LifeVantage Co. (NASDAQ:LFVN) Director Raymond B. Greer Sells 8,000 Shares

LifeVantage Co. (NASDAQ:LFVN - Get Free Report) Director Raymond B. Greer sold 8,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $20.15, for a total value of $161,200.00. Following the transaction, the director now owns 99,288 shares of the company's stock, valued at approximately $2,000,653.20. This trade represents a 7.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

LifeVantage Stock Up 0.7 %

LFVN stock traded up $0.12 during trading on Friday, hitting $18.56. 226,625 shares of the company's stock traded hands, compared to its average volume of 317,488. The business has a fifty day simple moving average of $19.78 and a two-hundred day simple moving average of $14.24. LifeVantage Co. has a 1 year low of $5.22 and a 1 year high of $27.38. The firm has a market capitalization of $232.93 million, a P/E ratio of 33.14 and a beta of 0.84.

LifeVantage (NASDAQ:LFVN - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 3rd will be given a $0.04 dividend. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $0.16 annualized dividend and a yield of 0.86%. LifeVantage's dividend payout ratio (DPR) is currently 28.57%.

Hedge Funds Weigh In On LifeVantage

Several institutional investors have recently modified their holdings of the stock. Barclays PLC boosted its stake in LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company's stock valued at $507,000 after buying an additional 11,608 shares in the last quarter. HighTower Advisors LLC bought a new position in LifeVantage during the 3rd quarter valued at approximately $638,000. Ritholtz Wealth Management boosted its stake in LifeVantage by 65.2% during the 4th quarter. Ritholtz Wealth Management now owns 47,348 shares of the company's stock valued at $830,000 after purchasing an additional 18,682 shares during the last quarter. Capital Management Corp VA bought a new position in LifeVantage in the 3rd quarter worth $5,073,000. Finally, Copeland Capital Management LLC purchased a new position in LifeVantage in the fourth quarter worth about $65,000. 35.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the company. Lake Street Capital initiated coverage on LifeVantage in a research note on Thursday, December 19th. They issued a "buy" rating and a $26.00 price target on the stock. Craig Hallum started coverage on LifeVantage in a research note on Tuesday, January 14th. They issued a "buy" rating and a $35.00 price target on the stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.